Patel K R
Br J Clin Pharmacol. 1986 Feb;21(2):234-7. doi: 10.1111/j.1365-2125.1986.tb05182.x.
In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC. The bronchodilation was observed within 5 min of the first dose. In a further nine patients tulobuterol 200 micrograms and 400 micrograms aerosol inhibited exercise-induced asthma following 6-8 min treadmill exercise and the effect was comparable to 200 micrograms salbutamol aerosol. Minor muscle tremors were observed in two patients with 400 micrograms of tulobuterol but no significant changes in pulse rate or blood pressure were noted.
在15例哮喘患者中,新型β2肾上腺素能受体激动剂妥洛特罗通过吸入给药,每次增加100微克,直至累积剂量达到600微克,可使第一秒用力呼气容积(FEV1)和用力肺活量(FVC)呈剂量相关增加。首次给药后5分钟内即可观察到支气管扩张。在另外9例患者中,200微克和400微克妥洛特罗气雾剂在6 - 8分钟跑步机运动后可抑制运动诱发的哮喘,其效果与200微克沙丁胺醇气雾剂相当。400微克妥洛特罗使2例患者出现轻微肌肉震颤,但未观察到脉搏率或血压有显著变化。